The revolutionary trend in the era of cancer therapeutics is brought by the development of monoclonal antibodies. Further exploration in this field has led to the emergence of their enhanced “bispecifics” counterparts.
China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
- China Bispecific Antibodies Market Sales Opportunity To Double By 2028
- Over Next 5 Years 3 Or 4 Bispecific Antibodies Are Expected To Be Available In Market
- Comprehensive Insight On Ongoing Bispecific Antibodies Clinical Trials By Phase, Company, Indication & Patient Segment
- Bispecific Antibodies Trials In China: > 250 Antibodies
- Comprehensive Insight On More Than 80 Bispecific Antibodies Available For Licensing/Partnership
- China Bispecific Antibodies Market Dynamics
- Insight On Key Chines Companies Developing Bispecific Antibodies
Download Report Sample:
https://www.kuickresearch.com/ccformF.php?t=1663763647
The revolutionary trend in the era of cancer therapeutics is brought by the development of monoclonal antibodies. Further exploration in this field has led to the emergence of their enhanced “bispecifics” counterparts. Bispecific antibodies are engineered artificial antibodies which have the ability to recognize two epitopes of an antigen or two antigens. The antibodies with two-target functionality have the potential to interfere with the multiple surface receptors or ligands associated with cancer, proliferation or inflammation. The advent of bispecific antibodies has conferred several potential advantages over monoclonal antibodies. The higher binding affinity of bispecific antibodies which can interact with more than one surface antigen led to enhancement in the cytotoxic effects due to the direct recruitment of effector cells on the site of the disease. In comparison to monoclonal antibodies, the bispecifics have small size and have the ability to pass through blood brain barrier.
Recently in 2022, Center for Drug Evaluation of the National Medical Products Administration (NMPA) of the People’s Republic of China has granted market authorization PD-1/CTLA-4 bi-specific antibody (Cadonilimab injection, AK104) or the treatment of relapsed or metastatic cervical cancer (R/M CC) patients who progressed on or after platinum-based chemotherapy. It is globally first dual immune checkpoint inhibitor bi-specific antibody approved for marketing. The approval is based on the encouraging result from phase-III clinical trial which shown to enhance the survival outcomes in patients.
The phenomenal success of bispecific antibodies with more than USD 10 billion cumulative sales since first approval has led to Chinese pharmaceutical companies to move ahead and look out of partnership/licensing deals with western counterparts to strengthen their research and commercialization efforts in order to drive the local bispecific market. As per our report findings currently more than 80 bispecific antibodies from more than 10 local Chinese pharmaceutical companies are available for licensing partnership. More than 20 of these bispecific antibodies available for the licensing are centric around targeted cancer therapeutics approach and are under Phase I or higher phase clinical trials.
There are several bispecific antibody platforms which have been developed in China that have aided in the development of the bispecific antibodies over a period. These include YBODY by YZY Biopharma, Immune-therapy antibody (iTab) by Generon Biomed (now Evive Biotech), Tetravalent Fabs-In-Tandem immunoglobulins (FIT-Ig) by EpimAb, Charge Repulsion Improved Bispecific (CRIB) by AlphaMab and nanoBiTE by Sysvax. These platforms help in producing antibodies with varying mechanisms of action, allow the comparative analysis of different antibodies and helps to develop antibodies which better safety and pharmacokinetic profiles.
As per our report finding, China bispecific antibody market is expected to double by 2028 from 2022 sales level with commercial launch or 3 or 4 more antibodies in the market. With increasing clinical development and large number of deals happening between local and western firms, the Chinese bispecific antibody market will emerge as lucrative other markets in years to come.
Contact:
Neeraj Chawla
Kuick Research
Research Head